FDA Brief

Warning letters Devices

FDA warning letter to

Tianjin Bolang Science-Technology Development Co., Ltd.

High riskIssued Jun 17, 2021Posted Aug 17, 2021Center for Devices and Radiological Health

FDA found Tianjin Bolang's otoscopes and rigid endoscopes failed device manufacturing rules after a 2021 inspection and is detaining imports.

What happened

FDA inspected the Tianjin facility from March 22 to March 30, 2021. The investigator found the firm lacked required design controls, corrective and preventive action (CAPA) procedures, complaint handling, distribution controls, device master and history records, a quality system record, and adequate training. FDA also found no written medical device reporting (MDR) procedures for its Class II Rigid Nasopharyngoscope and said the firm's responses were not adequate.

What FDA found

  1. The firm had no design control procedures or design activities for its private-label endoscopic devices, including the Class II Rigid Nasopharyngoscope.

    21 CFR 820.30(a)
  2. The firm had no corrective and preventive action procedures and did not collect quality data that could require such action.

    21 CFR 820.100(a)
  3. The firm had no complaint handling procedures or complaint records and no written agreement requiring its sole U.S. distributor to send complaints for review.

    21 CFR 820.198(a)
  4. The firm had no procedures to control distribution of finished devices and ensure only approved devices were released.

    21 CFR 820.160
  5. The firm did not maintain device master records or device history records for its private-label endoscopic devices.

    21 CFR 820.181; 21 CFR 820.184
  6. The firm had no written medical device reporting procedures, including how to submit reports electronically.

    21 CFR 803.17

What FDA wants

FDA asks the firm to respond in writing within 15 business days with the specific steps taken to correct the violations, documentation of corrections and corrective actions, and a timetable for any work not yet complete. FDA also asks for English translations of documents not in English.

Who should pay attention

  • U.S. distributors and importers of Tianjin Bolang endoscopes
  • private-label brands that source these devices
  • quality managers at medical device contract manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chirp Innovations, LLC

    FDA warned Chirp Innovations over quality-system gaps, missing adverse-event reporting procedures, and unapproved marketing of its Halo muscle stimulator for menstrual pain.

    High risk
  2. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  3. Linemaster Switch Corporation

    Linemaster Switch Corporation, a Connecticut maker of foot pedals for medical lasers, was cited for quality system failures after an FDA inspection.

    High risk
  4. BMC Medical Co., Ltd.

    BMC Medical’s G3X APAP devices were misbranded/adulterated after significant changes without a new 510(k) and an unreported firmware fix.

    High risk